NEW YORK and BURLINGTON, N.C., Feb. 07, 2024 (GLOBE NEWSWIRE) -- WeightWatchers (NASDAQ: WW), (“WeightWatchers,” “WW,” or the “Company”) today announced that Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, is deepening its existing partnership with WeightWatchers for Business to offer their full-spectrum weight health platform, with individualized pathways of both behavioral and clinical interventions, available at no cost to Labcorp’s U.S. employees. Spouses and domestic partners covered under a Labcorp medical plan are also eligible.
WeightWatchers for Business is the complete weight health platform designed for employers, payers, and health plans, providing science-proven behavior change programs, access to virtual clinic care, and medication management for those eligible.
“We’ve had a long-standing collaboration with WeightWatchers for Business, and we’re excited to expand on that partnership with this new comprehensive offering for our employees,” said Brian Caveney, M.D., Chief Medical and Scientific Officer, Labcorp. “From implementation to client management, WeightWatchers for Business makes it easy for Labcorp to offer our employees some of the best, most streamlined, and easy-to-navigate programs to meet and sustain their weight health goals.”
For nearly a decade, Labcorp has been a valued client of WeightWatchers for Business, incorporating its behavioral program into its benefits offerings. Building on the existing partnership, Labcorp and WeightWatchers for Business will expand this benefit to offer a full-spectrum weight health platform for Labcorp employees and their eligible spouses and domestic partners. This comprehensive approach delivers individualized pathways based on clinical need and is designed to optimize both the experience and outcomes for members. The result is an end-to-end solution covering everything from behavioral programs to access to clinical evaluations and treatment options, as well as medication management for those eligible and in need of a high-touch solution. Highlights of the program include:
“Labcorp and WeightWatchers for Business share a philosophy of opening access to a full spectrum of clinically proven weight health tools and resources,” said Amy Meister, D.O., Chief Medical Officer, WeightWatchers. “Implementing this comprehensive program reflects Labcorp’s commitment to their employees to ensure they have the holistic support they need to achieve sustained health outcomes.”
About WW International, Inc.
WeightWatchers is a human-centric technology company powered by our proven, science-based, clinically effective weight loss and weight management programs. For six decades, we have inspired millions of people to adopt healthy habits for real life. We combine technology and community to help members reach and sustain their goals on our programs. To learn more about the WeightWatchers approach to healthy living, please visit www.ww.com. For more information about our global business, visit our corporate website at www.corporate.ww.com.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's more than 60,000 employees serve clients in over 100 countries, worked on over 80% of the new drugs approved by the FDA in 2022 and performed more than 600 million tests for patients around the world. Learn more about us at www.labcorp.com.
1 Based on a 2020 IQVIA survey of 14,000 doctors who recommend weight-loss programs to patients.
Last Trade: | US$217.12 |
Daily Change: | -3.45 -1.56 |
Daily Volume: | 750,058 |
Market Cap: | US$18.160B |
April 02, 2025 February 06, 2025 December 17, 2024 November 04, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load